Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Design Therapeutics, Inc.NASDAQ: DSGN
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures turns positive
Q1 FY2026 capital expenditures was $0, compared with -$72K a year earlier. Trailing-twelve-month capital expenditures was -$121K. Over 3 fiscal years it compounded at -40.5% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$30.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (193K) USD
- Year-over-year change
- +43.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (193K) | +43.2% |
| FY2024 | 2024-12-31 | (340K) | -32.8% |
| FY2023 | 2023-12-31 | (256K) | +72.1% |
| FY2022 | 2022-12-31 | (918K) | +40.3% |
| FY2021 | 2021-12-31 | (1.54M) | — |
Capital Expenditures vs competitors
How DSGN compares with its peers on the latest reported figures
- DSGN's LTM Mar 2026 capital expenditures of $121K is the 10th largest of the 11 companies compared; the peer median is $1.09M.
- Its year-over-year change of -44.2% is the 8th highest of 11, against a peer median of +36.1%.
- Over three fiscal years its annual growth of -40.5% compares with a peer median of -16.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $302.05M | +1172.9% | +25.3% | 29.9% | |
| LTM Sep 2026 | $71.85M | +29.1% | +36.8% | 7.5% | |
| LTM Mar 2026 | $69.14M | -54.0% | +46.8% | 3.2% | |
| LTM Jun 2026 | $21.4M | +803.5% | -14.5% | — | |
| LTM Mar 2026 | $1.19M | +88.9% | -27.4% | — | |
| LTM Mar 2026 | $981.99K | +43.1% | -19.2% | 1.4% | |
| LTM Mar 2026 | $871K | +153.9% | -44.7% | 2.7% | |
| LTM Mar 2026 | $322K | +28.8% | -45.7% | — | |
| LTM Mar 2026 | $139K | -75.6% | -58.7% | — | |
| LTM Mar 2026 | $121K | -44.2% | -40.5% | — | |
| LTM Mar 2026 | $42K | -92.6% | -3.1% | — | |
| Peer median (excluding DSGN) | $1.09M | +36.1% | -16.8% | 3.2% | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Depreciation & Amortization | 129K | 406K | 537K | 596K | (2.63M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.69M | 10.93M | 13.09M | 13.07M | 14.55M |
| Change in Working Capital | 1.4M | 1.99M | 728K | (993K) | 3.11M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.41M | 5.39M | (1.25M) | (1.22M) | 4.49M |
| Other Working Capital | (1.02M) | (3.39M) | 1.97M | 226K | (1.38M) |
| Other Non-Cash Items | (58K) | (1.33M) | (6.05M) | (6.19M) | 406K |
| Operating Cash Flow | (29.38M) | (51.32M) | (58.56M) | (43.11M) | (54.36M) |
| Capital Expenditures | (1.54M) | (918K) | (256K) | (340K) | (193K) |
| Acquisitions (Net) | 52.11K | 39K | 0 | 0 | 0 |
| Purchases of Investments | (86.26M) | (313M) | (224.7M) | (230.18M) | (291.78M) |
| Sales of Investments | 34.16M | 92.89M | 277.5M | 274.47M | 314.89M |
| Other Investing Activities | (52.11K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (53.64M) | (220.99M) | 52.54M | 43.96M | 22.91M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 254.27M | 662K | 724K | 513K | 25.74M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 228K | (427K) | 0 | 0 | 0 |
| Financing Cash Flow | 379.21M | 235K | 724K | 513K | 25.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 296.19M | (272.07M) | (5.3M) | 1.36M | (5.71M) |
| Free Cash Flow | (30.92M) | (52.24M) | (58.82M) | (43.45M) | (54.55M) |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.